Min Zhu

33.9k total citations · 5 hit papers
288 papers, 25.9k citations indexed

About

Min Zhu is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Min Zhu has authored 288 papers receiving a total of 25.9k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 56 papers in Molecular Biology and 45 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Min Zhu's work include CAR-T cell therapy research (36 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Lymphoma Diagnosis and Treatment (22 papers). Min Zhu is often cited by papers focused on CAR-T cell therapy research (36 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Lymphoma Diagnosis and Treatment (22 papers). Min Zhu collaborates with scholars based in United States, China and Hong Kong. Min Zhu's co-authors include Marc H. Hedrick, Prosper Benhaim, Patricia A. Zuk, Jerry I. Huang, Hiroshi Mizuno, John K. Fraser, Helga Lorenz, J. William Futrell, Adam J. Katz and Peter Ashjian and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Min Zhu

273 papers receiving 25.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies

2001 6.1k citations Min Zhu, Marc H. Hedrick et al. profile →
Human Adipose Tissue Is a Source of Multipotent Stem Cells

2002 5.3k citations Min Zhu, John K. Fraser et al. profile →
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

2004 1.6k citations Koen Andries, Peter Verhasselt et al. Science profile →
Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow

2003 940 citations Zeni Alfonso, Min Zhu et al. profile →
Multipotential differentiation of adipose tissue-derived stem cells

2005 739 citations Brian M. Strem, Min Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Min Zhu United States	61	11.3k	8.0k	7.9k	3.3k	3.1k	288	25.9k
Yufang Shi China	79	9.9k 0.9×	4.8k 0.6×	11.5k 1.5×	1.3k 0.4×	5.5k 1.7×	352	30.5k
Joshua M. Hare United States	95	6.5k 0.6×	10.5k 1.3×	11.3k 1.4×	3.5k 1.1×	1.2k 0.4×	386	32.9k
Giovanni Camussi Italy	89	4.9k 0.4×	5.4k 0.7×	19.8k 2.5×	846 0.3×	2.8k 0.9×	572	33.7k
Michael D. Menger Germany	75	1.7k 0.1×	8.5k 1.1×	5.6k 0.7×	2.1k 0.6×	2.3k 0.7×	766	23.7k
Paul D. Robbins United States	105	2.7k 0.2×	5.6k 0.7×	18.6k 2.4×	781 0.2×	5.6k 1.8×	530	38.1k
Stefanie Dimmeler Germany	143	11.1k 1.0×	15.9k 2.0×	42.9k 5.5×	4.7k 1.4×	6.7k 2.2×	518	73.2k
Yasufumi Kaneda Japan	79	1.6k 0.1×	4.0k 0.5×	11.8k 1.5×	1.1k 0.3×	2.2k 0.7×	470	24.5k
Ryuichi Morishita Japan	81	1.7k 0.2×	5.7k 0.7×	11.1k 1.4×	1.0k 0.3×	2.2k 0.7×	586	25.4k
Jordan S. Pober United States	97	1.3k 0.1×	6.0k 0.8×	12.0k 1.5×	1.9k 0.6×	4.3k 1.4×	362	37.0k
Gou Young Koh South Korea	86	1.8k 0.2×	4.2k 0.5×	16.6k 2.1×	949 0.3×	4.8k 1.5×	274	29.2k

Countries citing papers authored by Min Zhu

Since Specialization

Citations

This map shows the geographic impact of Min Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Zhu more than expected).

Fields of papers citing papers by Min Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Zhu. The network helps show where Min Zhu may publish in the future.

Co-authorship network of co-authors of Min Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Min Zhu. A scholar is included among the top collaborators of Min Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min Zhu. Min Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Weiping, Jianping Wu, Hong Xiao, et al.. (2025). Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment. Cancer Immunology Immunotherapy. 74(4). 137–137. 2 indexed citations

Fei, Jiangang, Huan Liu, Min Zhu, et al.. (2025). In(OH)3-modified CuO nanosheets for CO2 electroreduction to promote C2 products and inhibit H2. Applied Surface Science. 703. 163421–163421. 1 indexed citations

Birhiray, Ruemu, Stefano Luminari, Tae Min Kim, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).. Journal of Clinical Oncology. 42(16_suppl). TPS7096–TPS7096. 2 indexed citations

Li, Xin, Min Zhu, Di Zhou, et al.. (2021). Rapamycin-reinforced ferroptosis assisted by a lysosome-controlled disintegratable micelle in autophagy-dependent/independent manners. Applied Materials Today. 23. 101066–101066. 6 indexed citations

Cooper, Dennis, Deepu Madduri, Suzanne Lentzsch, et al.. (2019). Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3176–3176. 31 indexed citations

Chen, Yuanyuan, Jiazhen Chen, Shuo Zhang, et al.. (2018). Novel Mutations Associated with Clofazimine Resistance in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 62(7). 28 indexed citations

Geng, Cuizhi, Qian Liang, Jian‐Hong Zhong, et al.. (2015). Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. BMJ Open. 5(6). e007258–e007258. 16 indexed citations

Doshi, Sameer, Per Olsson, Yilong Zhang, et al.. (2015). Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer. Clinical Cancer Research. 21(11). 2453–2461. 22 indexed citations

Yuan, Han, Lei Ding, Min Zhu, et al.. (2015). Reconstructing Large-Scale Brain Resting-State Networks from High-Resolution EEG: Spatial and Temporal Comparisons with fMRI. Brain Connectivity. 6(2). 122–135. 59 indexed citations

10.

Robertson, J.F.R., Jean-Marc Ferrero, Hugues Bourgeois, et al.. (2013). Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. The Lancet Oncology. 14(3). 228–235. 137 indexed citations

11.

Rosen, Lee S., Igor Puzanov, Gregory Friberg, et al.. (2012). Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(12). 3414–3427. 30 indexed citations

12.

Ryan, Charles J., Mark Rosenthal, Siobhan Ng, et al.. (2012). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clinical Cancer Research. 19(1). 215–224. 64 indexed citations

13.

Zhu, Min, Romaine E. Saxton, Lillian Ramos, et al.. (2011). Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis. Molecular Cancer Therapeutics. 10(8). 1500–1508. 64 indexed citations

14.

Zhu, Min, et al.. (2011). Sparse MEG source imaging in Landau-Kleffner syndrome. PubMed. 116. 4909–4912. 1 indexed citations

15.

Gordon, Michael S., Christopher J. Sweeney, David S. Mendelson, et al.. (2010). Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(2). 699–710. 133 indexed citations

16.

Beltran, Pedro J., Petia Mitchell, Elaina Cajulis, et al.. (2009). AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics. 8(5). 1095–1105. 113 indexed citations

17.

Strem, Brian M., Min Zhu, Zeni Alfonso, et al.. (2005). Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury. Cytotherapy. 7(3). 282–291. 113 indexed citations

18.

Andries, Koen, Peter Verhasselt, Jérôme Guillemont, et al.. (2004). A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science. 307(5707). 223–227. 1632 indexed citations breakdown →

19.

Zhu, Min, et al.. (1996). Chemical and Biological Investigation of the Root Bark ofClerodendrum mandarinorum. Planta Medica. 62(5). 393–396. 19 indexed citations

20.

Cheng, Leonard K. & Min Zhu. (1995). Mixed-Strategy Nash Equilibrium Based upon Expected Utility and Quadratic Utility. Games and Economic Behavior. 9(2). 139–150. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact